BURLINGAME, Calif. (PRWEB) November 19, 2018
The often-repeated claim that there is nothing that prevents, reverses, or delays Alzheimer’s disease is being aggressively challenged. In 2014, Dr. Dale Bredesen, Professor at UCLA, published the first examples of the reversal of cognitive decline in patients with Alzheimer’s disease using his personalized RECODE™ patient protocol. Initial reports were across a small group of 10 patients, followed by another 10 in 2016. Bredesen, along with colleagues from 15 different clinical sites, has just published a paper describing 100 patients with Alzheimer’s or pre-Alzheimer’s who had well documented, quantified improvements in cognition. In addition, some patients demonstrated improvements in quantitative EEG, evoked responses, or hippocampal volume, providing further support for the efficacy of the protocol. Some of the improvements were striking, with 12-point jumps in Montreal Cognitive Assessment (MoCA) scores. The results in these 100 patients were published in the Journal of Alzheimer’s Disease and Parkinsonism, providing further support for a randomized, controlled clinical trial of the protocol and the overall approach.
The full report can be read here: https://www.omicsonline.org/open-access/reversal-of-cognitive-decline-100-patients-2161-0460-1000450.pdf
AHNP Precision Health is a patient engagement company focused on precision health that empowers patients, practitioners, hospitals, universities, and corporations to prevent and reverse behavior-related or exposure-related chronic diseases through advanced medical information, algorithms, and scientifically supported behavior modification. Its RECODE REPORT™ analyses are based on The Bredesen Protocol; a comprehensive personalized program designed to improve cognition and reverse the cognitive decline of SCI, MCI, and early Alzheimer’s disease designed by Alzheimer’s research pioneer and AHNP CSO, Dr. Dale Bredesen.
For more information, please visit our website at:
PR Contact: Lance Kelly, email@example.com